Clinical trials: Hepatic Cirrhosis
Sexual Dysfunction in Patients With Cirrhosis Awaiting Liver Transplantation
Sexual Dysfunction in Cirrhosis
The prevalence of erectile dysfunction (ED) is about 10% in the general population, but increases with age, ranging from 9.1% in men 40-49 years to 55% in men >70.
- Trial name
- SEDYC (NCT05428267)
- Testing
- questionnaire, blood collection
- Where
- France
- Volunteers
- 230 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatitis C, Chronic, Liver Cirrhosis
Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116)
The objective is to evaluate the efficacy and safety of combination therapy with peginterferon alfa-2b 1.0 µg/kg/week subcutaneous (SC) + ribavirin administered for 48 weeks in participants with chronic hepatitis C and type C…
- Trial name
- NCT00687219
- Testing
- Peginterferon alfa-2b, Ribavirin
- Volunteers
- 102 people
- Sponsor
- Merck Sharp & Dohme LLC
Alcohol Use Disorder, Alcohol-associated Liver Disease
Pomegranate Dietary Supplements in AUD and ALD
The goal of this project is to determine an individual's ability to generate active gut microbial metabolites called urolithins upon consumption of pomegranate dietary supplements.
- Conditions
- Alcohol Use Disorder, Alcohol-associated Liver Disease, Alcoholic Cirrhosis, Healthy
- Trial name
- NCT07678567
- Testing
- Pomegranate Dietary Ssupplement
- Where
- United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- University of Louisville
Chronic Hepatitis C, Hepatic Fibrosis
Prediction of Hepatic Fibrosis in Patients With Chronic Hepatitis C by Biochemical and Duplex Doppler Indices
The purpose of our prospective study was to evaluate the value of Doppler parameters and compare the diagnostic accuracy of Doppler parameters with various biochemical indices in predicting significant hepatic fibrosis (≥ F2) and…
- Conditions
- Chronic Hepatitis C, Hepatic Fibrosis, Cirrhosis
- Trial name
- NCT00466336
- Where
- Taiwan
- Volunteers
- 503 people
- Sponsor
- National Taiwan University Hospital
Primary Biliary Cholangitis
Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS0159 in Chinese Healthy Subjects
This is a phase I clinical bridging trial, randomized, double-blind, placebo-controlled, single ascending does/ mulelple ascending does study of CS0159 to evaluate the safety, tolerability, pharmacokynetics, pharmacodynamices…
- Trial name
- NCT05624294
- Testing
- CS0159
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Cascade Pharmaceuticals, Inc
Liver Fibrosis
HBsAg Seroclearance in Adults With HBV Related Liver Fibrosis After Receiving Combined Therapy of Peg-IFN and Tenofovir.
Liver fibrosis caused by hepatitis B virus (HBV) infection is easy to progress to liver cirrhosis and liver cancer, with great harm and poor therapeutic effect.
- Trial name
- NCT04640129
- Testing
- PEG-Interferon Alfa, Tenofovir Disoproxil Fumarate, Tenofovir Disoproxil Fumarate
- Where
- China
- Volunteers
- 336 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Portal Vein Thrombosis
Nadroparin Versus TIPS in Cirrhotic Patients With Refractory Asymptomatic PVT
The purpose of this study is to evaluate the comparative effectiveness of nadroparin versus transjugular intrahepatic portosystemic shunt in cirrhotic patients with refractory asymptomatic portal vein thrombosis using a design of…
- Trial name
- NCT06319131
- Testing
- TIPS, Nadroparin
- Volunteers
- 84 people
- Sponsor
- Shanghai Zhongshan Hospital
Cirrhosis
Infections in Hospitalized Cirrhotic Patients
Hospitalized cirrhotic patients are at high risk of complications and adverse outcomes. This study aims to determine the current practice and outcomes in these following areas: 1. Community-acquired infections 2.
- Trial name
- NCT03137719
- Volunteers
- 385 people
- Sponsor
- Baylor Research Institute
Portal Hypertension Related to Cirrhosis
Small Diameter TIPS in Patients with Severe Liver Atrophy and Variceal Bleeding
Portal hypertension is the most common complication in patients with end-stage liver cirrhosis. Portal hypertension-related complications, such as variceal bleeding, often lead to a poor prognosis.
- Trial name
- NCT06589531
- Testing
- During TIPS operation, shunt diameter or diameter of covered stent
- Volunteers
- 120 people
- Sponsor
- Huang Mingsheng
Liver Cirrhosis
Evaluate Safety and Efficacy of Autologous Bone Marrow-derived Endothelial Progenitor Cells in Advanced Liver Cirrhosis
Endothelial Progenitor Cells (EPC) represent a small cellular population of bone marrow and peripheral blood cells. EPCs are recruited into injured tissues and play an important role in regeneration and reparation.
- Trial name
- NCT01333228
- Testing
- Autologous bone marrow-derived endothelial progenitor cells
- Where
- Spain
- Volunteers
- 14 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Decompensated Liver Cirrhosis, Cirrhosis
Statin and Beta Blocker Use in Patients With Decompensated Cirrhosis
Decompensated cirrhosis (liver disease) occurs when liver function decreases to the extent that serious complications develop and can include internal bleeding, fluid buildup in the abdomen, or mental confusion.
- Conditions
- Decompensated Liver Cirrhosis, Cirrhosis, Decompensated Cirrhosis of Liver, Decompensated Cirrhosis and Ascites
- Trial name
- NCT06764966
- Testing
- Atorvastatin 20 mg
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- CAMC Health System
Acute Upper Gastrointestinal Bleeding, Acute Variceal Bleeding
Timing of Endoscopy in Cirrhotic Patients With Acute Variceal Bleeding
Endoscopy is important for the diagnosis and treatment of acute upper gastrointestinal bleeding (AUGIB), especially acute variceal bleeding (AVB), in patients with liver cirrhosis.
- Trial name
- NCT06031402
- Testing
- Endoscopy
- Where
- China
- Volunteers
- 368 people
- Sponsor
- General Hospital of Shenyang Military Region
Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis
Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects
The purpose of this study is to directly characterize the pharmacokinetic (PK) profiles of MGL-3196 and its major metabolite (MGL-3623) following administration of multiple oral doses (QD x 6 days) in subjects with varying…
- Conditions
- Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver
- Trial name
- NCT04643795
- Testing
- MGL-3196
- Where
- 3 sites in United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Madrigal Pharmaceuticals, Inc.
Cirrhosis
Propofol and Fentanyl Versus Midazolam and Fentanyl for Endoscopy Sedation in Cirrhotic Patients
The purpose of this study is to compare propofol associated with fentanyl versus midazolam plus fentanyl for sedation during diagnosis or therapeutic upper gastrointestinal endoscopy (UGE) in cirrhotic patients.
- Trial name
- NCT00906139
- Testing
- Propofol, Midazolam, Fentanyl
- Where
- Brazil
- Volunteers
- 210 people
- Sponsor
- Federal University of São Paulo
Primary Biliary Cholangitis, Liver Stiffness
A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness
The primary objective of this study is to evaluate the effect of setanaxib on alkaline phosphatase (ALP) at Week 24 in participants with PBC and with elevated liver stiffness and intolerance or inadequate response to…
- Trial name
- TRANSFORM (NCT05014672)
- Testing
- Setanaxib
- Where
- 128 sites in United States, Australia and 16 more
- Volunteers
- 76 people
- Sponsor
- Calliditas Therapeutics Suisse SA
HBV
Clinical Study of hUC-MSCs Treating Decompensated Liver Cirrhosis With HBV
The purpose of this study was to observe the safety ,tolerability ,Efficacy dose of human umbilical cord mesenchymal stem cells in patients of decompensated liver cirrhosis with HBV.
- Trial name
- CS-hUC-MSCs (NCT05442437)
- Testing
- hUCMSCs
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Zhongnan Hospital
Hepatic Cirrhosis, Liver Fibrosis
A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis
This is a study of experimental medication BMS-986036 given to adults with Nonalcoholic Steatohepatitis (NASH; the buildup of fat and inflammation in the liver that is not caused by alcohol) and liver cirrhosis (liver damage…
- Conditions
- Hepatic Cirrhosis, Liver Fibrosis, Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis
- Trial name
- FALCON 2 (NCT03486912)
- Testing
- BMS-986036
- Where
- 91 sites in United States, Japan
- Volunteers
- 155 people
- Sponsor
- Bristol-Myers Squibb
Cirrhosis
Tips Underdilatation in Patients With Cirrhosis
The transjugular intrahepatic portosystemic shunt (TIPS) is a well-established procedure for the treatment of portal hypertensive bleeding, refractory ascites and vascular diseases of the liver.
- Trial name
- NCT03363412
- Testing
- PTFE-covered stent grafts
- Where
- 2 sites in Italy
- Volunteers
- 148 people
- Sponsor
- University of Modena and Reggio Emilia
Carcinoma, Hepatocellular
Harms of Hepatocellular Carcinoma Surveillance
This study leverage a multi-center randomized controlled trial assessing screening-related benefits (i.e. early tumor detection, treatment eligibility, and overall survival) among a racially and socioeconomically diverse…
- Trial name
- NCT03756051
- Testing
- Prospective Longitudinal Data, Surveys and Semi-structured Interviews
- Where
- United States
- Volunteers
- 2,871 people
- Sponsor
- University of Texas Southwestern Medical Center
Severe Alcoholic Hepatitis
LiverTREM-1: Hepatic TREM-1 Expression and Prognosis in Severe Alcoholic Hepatitis
Background \& Rationale Severe alcohol-related hepatitis (SAH) is a serious condition with a 3-month mortality rate of ~30%. Diagnosis and prognosis are complex due to non-specific and insensitive clinical, biological, and…
- Trial name
- Liver TREM-1 (NCT07176741)
- Testing
- TREM-1 expression (via immunohistochemistry) between SAH patients and controls
- Volunteers
- 300 people
- Sponsor
- Central Hospital, Nancy, France
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.